Detection of Pyrazinamide Heteroresistance in Mycobacterium tuberculosis

Heteroresistance is defined as the coexistence of both susceptible and resistant bacteria in a bacterial population. Previously published data show that it may occur in 9 to 57% of Mycobacterium tuberculosis isolates for various drugs. Pyrazinamide (PZA) is an important first-line drug used for trea...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy Vol. 65; no. 9; p. e0072021
Main Authors: Werngren, Jim, Mansjö, Mikael, Glader, Mikaela, Hoffner, Sven, Davies Forsman, Lina
Format: Journal Article
Language:English
Published: United States 17.08.2021
Subjects:
Amidohydrolases - genetics
Antitubercular Agents - pharmacology
Antitubercular Agents - therapeutic use
Drug Resistance, Bacterial - genetics
Humans
Microbial Sensitivity Tests
Mutation
Mycobacterium tuberculosis - genetics
Pyrazinamide - pharmacology
Tuberculosis, Multidrug-Resistant - drug therapy
Mycobacterium tuberculosis
heteroresistance
Wayne's test
whole-genome sequencing
method evaluation
pyrazinamide
drug susceptibility testing
BACTEC MGIT 960
ISSN:1098-6596, 1098-6596
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Heteroresistance is defined as the coexistence of both susceptible and resistant bacteria in a bacterial population. Previously published data show that it may occur in 9 to 57% of Mycobacterium tuberculosis isolates for various drugs. Pyrazinamide (PZA) is an important first-line drug used for treatment of both drug-susceptible and PZA-susceptible multidrug-resistant TB. Clinical PZA resistance is defined as a proportion of resistant bacteria in the isolate exceeding 10%, when the drug is no longer considered clinically effective. The ability of traditional drug susceptibility testing techniques to detect PZA heteroresistance has not yet been evaluated. The aim of this study was to compare the capacity of Bactec MGIT 960, Wayne's test, and whole-genome sequencing (WGS) to detect PZA-resistant subpopulations in bacterial suspensions prepared with different proportions of mutant strains. Both Bactec MGIT 960 and WGS were able to detect the critical level of 10% PZA heteroresistance, whereas Wayne's test failed to do so, with the latter falsely reporting highly resistant samples as PZA susceptible. Failure to detect drug-resistant subpopulations may lead to inadvertently weak treatment regimens if ineffective drugs are included, with the risk of treatment failure with the selective growth of resistant subpopulations. We need clinical awareness of heteroresistance as well as evaluation of new diagnostic tools for their capacity to detect heteroresistance in TB.
AbstractList Heteroresistance is defined as the coexistence of both susceptible and resistant bacteria in a bacterial population. Previously published data show that it may occur in 9 to 57% of Mycobacterium tuberculosis isolates for various drugs. Pyrazinamide (PZA) is an important first-line drug used for treatment of both drug-susceptible and PZA-susceptible multidrug-resistant TB. Clinical PZA resistance is defined as a proportion of resistant bacteria in the isolate exceeding 10%, when the drug is no longer considered clinically effective. The ability of traditional drug susceptibility testing techniques to detect PZA heteroresistance has not yet been evaluated. The aim of this study was to compare the capacity of Bactec MGIT 960, Wayne's test, and whole-genome sequencing (WGS) to detect PZA-resistant subpopulations in bacterial suspensions prepared with different proportions of mutant strains. Both Bactec MGIT 960 and WGS were able to detect the critical level of 10% PZA heteroresistance, whereas Wayne's test failed to do so, with the latter falsely reporting highly resistant samples as PZA susceptible. Failure to detect drug-resistant subpopulations may lead to inadvertently weak treatment regimens if ineffective drugs are included, with the risk of treatment failure with the selective growth of resistant subpopulations. We need clinical awareness of heteroresistance as well as evaluation of new diagnostic tools for their capacity to detect heteroresistance in TB.
Heteroresistance is defined as the coexistence of both susceptible and resistant bacteria in a bacterial population. Previously published data show that it may occur in 9 to 57% of Mycobacterium tuberculosis isolates for various drugs. Pyrazinamide (PZA) is an important first-line drug used for treatment of both drug-susceptible and PZA-susceptible multidrug-resistant TB. Clinical PZA resistance is defined as a proportion of resistant bacteria in the isolate exceeding 10%, when the drug is no longer considered clinically effective. The ability of traditional drug susceptibility testing techniques to detect PZA heteroresistance has not yet been evaluated. The aim of this study was to compare the capacity of Bactec MGIT 960, Wayne's test, and whole-genome sequencing (WGS) to detect PZA-resistant subpopulations in bacterial suspensions prepared with different proportions of mutant strains. Both Bactec MGIT 960 and WGS were able to detect the critical level of 10% PZA heteroresistance, whereas Wayne's test failed to do so, with the latter falsely reporting highly resistant samples as PZA susceptible. Failure to detect drug-resistant subpopulations may lead to inadvertently weak treatment regimens if ineffective drugs are included, with the risk of treatment failure with the selective growth of resistant subpopulations. We need clinical awareness of heteroresistance as well as evaluation of new diagnostic tools for their capacity to detect heteroresistance in TB.Heteroresistance is defined as the coexistence of both susceptible and resistant bacteria in a bacterial population. Previously published data show that it may occur in 9 to 57% of Mycobacterium tuberculosis isolates for various drugs. Pyrazinamide (PZA) is an important first-line drug used for treatment of both drug-susceptible and PZA-susceptible multidrug-resistant TB. Clinical PZA resistance is defined as a proportion of resistant bacteria in the isolate exceeding 10%, when the drug is no longer considered clinically effective. The ability of traditional drug susceptibility testing techniques to detect PZA heteroresistance has not yet been evaluated. The aim of this study was to compare the capacity of Bactec MGIT 960, Wayne's test, and whole-genome sequencing (WGS) to detect PZA-resistant subpopulations in bacterial suspensions prepared with different proportions of mutant strains. Both Bactec MGIT 960 and WGS were able to detect the critical level of 10% PZA heteroresistance, whereas Wayne's test failed to do so, with the latter falsely reporting highly resistant samples as PZA susceptible. Failure to detect drug-resistant subpopulations may lead to inadvertently weak treatment regimens if ineffective drugs are included, with the risk of treatment failure with the selective growth of resistant subpopulations. We need clinical awareness of heteroresistance as well as evaluation of new diagnostic tools for their capacity to detect heteroresistance in TB.
Author Davies Forsman, Lina
Mansjö, Mikael
Hoffner, Sven
Werngren, Jim
Glader, Mikaela
Author_xml – sequence: 1
  givenname: Jim
  surname: Werngren
  fullname: Werngren, Jim
  organization: Department of Microbiology, The Public Health Agency of Swedengrid.419734.c, Stockholm, Sweden
– sequence: 2
  givenname: Mikael
  surname: Mansjö
  fullname: Mansjö, Mikael
  organization: Department of Microbiology, The Public Health Agency of Swedengrid.419734.c, Stockholm, Sweden
– sequence: 3
  givenname: Mikaela
  surname: Glader
  fullname: Glader, Mikaela
  organization: Department of Microbiology, The Public Health Agency of Swedengrid.419734.c, Stockholm, Sweden
– sequence: 4
  givenname: Sven
  surname: Hoffner
  fullname: Hoffner, Sven
  organization: Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden
– sequence: 5
  givenname: Lina
  surname: Davies Forsman
  fullname: Davies Forsman, Lina
  organization: Department of Infectious Disease, Karolinska University Hospital, Stockholm, Sweden
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34181476$$D View this record in MEDLINE/PubMed
BookMark eNpNjz1PwzAQhi1URD9gY0YZWVJsxznbY1U-ilQEA8yR41wko8QudjKUX08kisR07-l5dLp3SWY-eCTkmtE1Y1zdbTbbNaWS05yzM7JgVKscSg2zf3lOlil9UkqnhV6QeSGYYkLCguzucUA7uOCz0GZvx2i-nTe9azDbTSSGiMmlwXiLmfPZy9GG2tgJuLHPhrHGaMcuTMolOW9Nl_DqNFfk4_HhfbvL969Pz9vNPjeihCE3wKevNci2QCFqXRgmygasQsGbgiHjqIFijbrFmoFUKKEtAEErZSTjfEVuf-8eYvgaMQ1V75LFrjMew5gqXgoAyiWjk3pzUse6x6Y6RNebeKz-2vMfYDFdMQ
CitedBy_id crossref_primary_10_1016_j_micres_2024_127701
crossref_primary_10_1016_j_jmoldx_2023_02_003
crossref_primary_10_1128_spectrum_02181_24
crossref_primary_10_1016_j_crmicr_2025_100462
crossref_primary_10_1016_j_tube_2024_102522
crossref_primary_10_1099_jmm_0_002048
crossref_primary_10_1016_j_tube_2023_102411
crossref_primary_10_1128_spectrum_01545_24
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1128/AAC.00720-21
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
Biology
Pharmacy, Therapeutics, & Pharmacology
EISSN 1098-6596
ExternalDocumentID 34181476
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.55
0R~
23M
2WC
39C
4.4
53G
5GY
5RE
5VS
6J9
AAGFI
ACGFO
ADBBV
AENEX
AGVNZ
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BTFSW
CGR
CS3
CUY
CVF
DIK
E3Z
EBS
ECM
EIF
F5P
FRP
GX1
H13
HH5
HYE
HZ~
H~9
K-O
KQ8
L7B
LSO
NPM
O9-
OK1
P2P
RHI
RNS
RPM
RSF
TR2
UHB
W2D
W8F
WH7
WOQ
X7M
7X8
ID FETCH-LOGICAL-a456t-a62112967f3e44b93a145d6c8e42d31e12e960ebe9feb1678e76f36e6988a7122
IEDL.DBID 7X8
ISICitedReferencesCount 7
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000707901200033&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1098-6596
IngestDate Thu Sep 04 18:31:07 EDT 2025
Mon Jul 21 05:35:35 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 9
Keywords Mycobacterium tuberculosis
heteroresistance
Wayne's test
whole-genome sequencing
method evaluation
pyrazinamide
drug susceptibility testing
BACTEC MGIT 960
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a456t-a62112967f3e44b93a145d6c8e42d31e12e960ebe9feb1678e76f36e6988a7122
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC8370246
PMID 34181476
PQID 2546602710
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2546602710
pubmed_primary_34181476
PublicationCentury 2000
PublicationDate 20210817
PublicationDateYYYYMMDD 2021-08-17
PublicationDate_xml – month: 8
  year: 2021
  text: 20210817
  day: 17
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Antimicrobial agents and chemotherapy
PublicationTitleAlternate Antimicrob Agents Chemother
PublicationYear 2021
SSID ssj0006590
Score 2.4173784
Snippet Heteroresistance is defined as the coexistence of both susceptible and resistant bacteria in a bacterial population. Previously published data show that it may...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage e0072021
SubjectTerms Amidohydrolases - genetics
Antitubercular Agents - pharmacology
Antitubercular Agents - therapeutic use
Drug Resistance, Bacterial - genetics
Humans
Microbial Sensitivity Tests
Mutation
Mycobacterium tuberculosis - genetics
Pyrazinamide - pharmacology
Tuberculosis, Multidrug-Resistant - drug therapy
Title Detection of Pyrazinamide Heteroresistance in Mycobacterium tuberculosis
URI https://www.ncbi.nlm.nih.gov/pubmed/34181476
https://www.proquest.com/docview/2546602710
Volume 65
WOSCitedRecordID wos000707901200033&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEB5848XH-lpfRBBPBtu0TdKTLOqyl116WGFvJU1TWNB23YfQf--k7dKTIHgpObQQkq8z32Qm3wDc-zLhjicVFY5W1FdGUSUcQZVWxmRSCeHVzSbEaCQnkzBqDtwWTVnl2iZWhjottD0jf7K67RxjKNd5nn1R2zXKZlebFhqbsO0hlbGoFpNWLZwHYa1GEEqKY74ufGfyqdd7qVSzHcrc38ll5WT6h_-d3hEcNPSS9Go8HMOGyTuwWzecLDuwN2xS6R14iGrR6vKRjNs7WItH8kCiVs66PIHBq1lW9Vo5KTISlXMrSK0-p6khA1tLU2DAbkkooodMczIsNZqISgJ69UmWq8TM9eqjwFdO4b3_Nn4Z0Kb_AlVIq5ZUcWbZGBeZZ3w_CT3l-kHKtTQ-Sz3XuMxg_IMoCDO0-Oj1jOCZxw0PJW6yy9gZbOVFbi6AcOSRQYpsXurE11mi0lAHGJprEWiWeU4X7tbLGiO-bdJC5aZYLeJ2YbtwXu9NPKuFOGL0wNL1Bb_8w9dXsM9sOYpVsxXXsJ3h321uYEd_L6eL-W0FHHyOouEP6HPNxw
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Detection+of+Pyrazinamide+Heteroresistance+in+Mycobacterium+tuberculosis&rft.jtitle=Antimicrobial+agents+and+chemotherapy&rft.au=Werngren%2C+Jim&rft.au=Mansj%C3%B6%2C+Mikael&rft.au=Glader%2C+Mikaela&rft.au=Hoffner%2C+Sven&rft.date=2021-08-17&rft.eissn=1098-6596&rft.volume=65&rft.issue=9&rft.spage=e0072021&rft_id=info:doi/10.1128%2FAAC.00720-21&rft_id=info%3Apmid%2F34181476&rft_id=info%3Apmid%2F34181476&rft.externalDocID=34181476
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1098-6596&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1098-6596&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1098-6596&client=summon